Articles related to RISK ASSESSMENT

A prospective study involving over 170,000 participants from the UK Biobank found that moderate coffee consumption (3 drinks/day) was associated with a 48.1% lower risk of developing cardiometabolic multimorbidity compared to non-consumers.

Recent research comparing SGLT2 inhibitors and dulaglutide in older patients with type 2 diabetes suggests a potential difference in dementia risk. The study estimated a risk ratio of 0.81 (CI, 0.56 to 1.16) for SGLT2 inhibitors compared to dulaglutide.

The PREVENT equation, developed by the American Heart Association in 2023, aims to provide a more accurate cardiovascular risk assessment for today’s population, potentially reducing statin prescriptions by 40%.

Infrequent soft stools were associated with higher risks of all-cause, cancer, and cardiovascular disease mortality, suggesting that stool monitoring could be a valuable indicator of major chronic illnesses.

Recent findings indicate that statin-naïve ACS patients with normal LDL-C levels at admission may face worse outcomes, challenging current perspectives on lipid management in cardiovascular care.

Statins remain a cornerstone of cardiovascular disease prevention, but managing potential side effects is key to ensuring patient adherence and optimal outcomes. This article provides a comprehensive overview of statin-associated adverse effects and practical management strategies for clinicians.